1,3-Benzenediboronic Acid: A Key Intermediate for Pharmaceutical & OLED Synthesis
In the fast-paced world of chemical innovation, access to reliable, high-purity intermediates is crucial for driving progress. 1,3-Benzenediboronic Acid, identified by CAS number 4612-28-6, has emerged as a vital compound, particularly in the synthesis of pharmaceuticals and advanced materials for OLED technology. NINGBO INNO PHARMCHEM CO.,LTD., a leading chemical manufacturer and supplier in China, is dedicated to providing this essential building block to meet the demanding needs of global industries.
The chemical profile of 1,3-Benzenediboronic Acid (molecular formula C6H8B2O4, molecular weight 165.75) reveals its key structural features: a benzene ring substituted with two boronic acid groups at the meta positions. This specific arrangement makes it an exceptionally useful substrate for palladium-catalyzed cross-coupling reactions, most notably the Suzuki-Miyaura coupling. This reaction is a powerful tool in modern organic synthesis, enabling the efficient formation of carbon-carbon bonds, which is fundamental for constructing complex molecules.
Within the pharmaceutical sector, 1,3-Benzenediboronic Acid functions as a critical pharmaceutical intermediate. Its involvement in the synthesis of various drug molecules makes it an indispensable component for drug discovery and development programs. Procurement managers seeking to buy 1,3-benzenediboronic acid value its high purity and consistent reactivity, which are vital for ensuring the efficacy and safety of final drug products. Sourcing from reputable Chinese manufacturers like NINGBO INNO PHARMCHEM ensures a stable supply chain, facilitating the efficient development and production of life-saving medicines.
Furthermore, 1,3-Benzenediboronic Acid plays a significant role in the field of OLED and electronic materials. Its ability to facilitate the creation of molecules with specific electronic and optical properties makes it a valuable ingredient for manufacturers developing next-generation display technologies and organic electronic devices. The precision offered by this intermediate is key to achieving the desired performance characteristics in these advanced applications. As a specialized supplier of electronic chemicals, NINGBO INNO PHARMCHEM understands these precise requirements.
The compound's inherent reactivity also positions it as a potentially valuable reagent in various catalytic processes or as a precursor for novel ligand design in organic chemistry, offering further avenues for synthetic optimization.
For businesses looking to procure this essential chemical, partnering with leading Chinese manufacturers offers significant advantages, including competitive pricing and a commitment to quality. NINGBO INNO PHARMCHEM CO.,LTD. prides itself on offering 1,3-Benzenediboronic Acid with guaranteed high purity and reliable availability. We are equipped to support your projects, from small-scale R&D needs to large-volume industrial requirements. When you need to purchase 1,3-benzenediboronic acid, our expertise and dedication to customer satisfaction make us your premier choice.
In summary, 1,3-Benzenediboronic Acid (CAS 4612-28-6) is a vital intermediate for critical sectors such as pharmaceuticals and OLED technology. Its versatility and reactivity empower chemists to develop innovative products. We invite you to partner with NINGBO INNO PHARMCHEM for your supply needs, ensuring quality and efficiency in your chemical endeavors.
Perspectives & Insights
Alpha Spark Labs
“Its involvement in the synthesis of various drug molecules makes it an indispensable component for drug discovery and development programs.”
Future Pioneer 88
“Procurement managers seeking to buy 1,3-benzenediboronic acid value its high purity and consistent reactivity, which are vital for ensuring the efficacy and safety of final drug products.”
Core Explorer Pro
“Sourcing from reputable Chinese manufacturers like NINGBO INNO PHARMCHEM ensures a stable supply chain, facilitating the efficient development and production of life-saving medicines.”